Molecular epidemiology of carbapenem-resistant Pseudomonas aeruginosa in an endemic area: comparison with global data
- 11 April 2018
- journal article
- review article
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 37 (7) , 1211-1220
Abstract
Carbapenem-resistant Pseudomonas aeruginosa (CRPA) is an endemic problem in certain countries including Greece. CRPA and multidrug-resistant P. aeruginosa (MDRPA) firstly emerged in our region during the 80s, right after the launch of imipenem and meropenem as therapeutic agents against P. aeruginosa infections. The role of outer membrane protein (Opr) inactivation has been known to contribute to imipenem resistance since many years, while efflux overexpression systems have been mainly associated with meropenem resistance. Among carbapenemases, metallo-β-lactamases (MBL) and mostly Verona integron-mediated (VIM) MBL’s have played the most crucial role in CRPA emergence. VIM-2 and VIM-4 producing CRPA, usually belonging to clonal complexes (CC) 111 and 235 respectively, have most frequently been isolated. BlaVIM-2 and blaVIM-4 are usually associated with a class 1 integron. VIM-17 also has appeared in Greece. On the other hand, other VIM subtypes detected in a global level, such as VIM-3, VIM-5, VIM-6, VIM-7, VIM-11, VIM-14, VIM-15, VIM-16 and VIM-18 have not yet emerged in Greece. However, new VIM subtypes will probably emerge in the future. In addition, MBL carbapenemases other than VIM, detected worldwide have not yet appeared. A single CRPA isolate producing KPC has emerged in our region several years ago. The study of the molecular basis of Opr deficiency and efflux overexpression remains a challenge for the future. In this article, we review the molecular epidemiology of CRPA in an endemic area, compared to global data.Keywords
This publication has 112 references indexed in Scilit:
- Infections in intensive care unit adult patients harboring multidrug-resistant Pseudomonas aeruginosa: implications for prevention and therapyEuropean Journal of Clinical Microbiology & Infectious Diseases, 2017
- The first report of detecting the bla SIM-2 gene and determining the complete sequence of the SIM-encoding plasmidClinical Microbiology and Infection, 2016
- Detection and termination of an extended low-frequency hospital outbreak of GIM-1–producing Pseudomonas aeruginosa ST111 in GermanyAmerican Journal of Infection Control, 2015
- Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative BacilliDrugs, 2013
- Current Therapies for Pseudomonas AeruginosaCritical Care Clinics, 2008
- Evaluation of SDS‐polyacrylamide gel systems for the study of outer membrane protein profiles of clinical strains of Acinetobacter baumanniiJournal of Basic Microbiology, 2003
- Macrorestriction analysis ofPseudomonas aeruginosa in colonized burn patientsEuropean Journal of Clinical Microbiology & Infectious Diseases, 1994
- Importance of carbenicillin and gentamicin cross-resistant serotype 0 : 12Pseudomonas aeruginosa in six Athens hospitalsEuropean Journal of Clinical Microbiology & Infectious Diseases, 1987
- Aminoglycosides plus beta-lactams against gram-negative organisms: Evaluation of in vitro synergy and chemical interactionsThe American Journal of Medicine, 1986
- Carbapenems, a new class of beta-lactam antibioticsThe American Journal of Medicine, 1985